Cambridge Investment Research Advisors’s HEXO Corp. Common Shares HEXO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-988
Closed -$2K 3238
2022
Q3
$2K Sell
988
-59
-6% -$168 ﹤0.01% 3049
2022
Q2
$3K Sell
1,047
-17
-2% -$81 ﹤0.01% 3039
2022
Q1
$9K Sell
1,064
-9
-0.8% -$77 ﹤0.01% 3146
2021
Q4
$10K Buy
1,073
+47
+5% +$873 ﹤0.01% 3152
2021
Q3
$26K Sell
1,026
-432
-30% -$20K ﹤0.01% 3050
2021
Q2
$118K Buy
1,458
+589
+68% +$51.3K ﹤0.01% 2945
2021
Q1
$79K Buy
+869
New +$84.6K ﹤0.01% 2784
2020
Q4
Sell
-590
Closed -$22K 2803
2020
Q3
$22K Sell
590
-100
-14% -$3.99K ﹤0.01% 2488
2020
Q2
$29K Buy
690
+256
+59% +$9.27K ﹤0.01% 2407
2020
Q1
$20K Sell
434
-79
-15% -$5.32K ﹤0.01% 2239
2019
Q4
$46K Sell
513
-30
-6% -$3.95K ﹤0.01% 2358
2019
Q3
$120K Buy
+543
New +$135K ﹤0.01% 2214
2019
Q2
Sell
-197
Closed -$73K 2390
2019
Q1
$73K Buy
+197
New +$63.8K ﹤0.01% 2208

Other funds holding HEXO

Cambridge Investment Research Advisors's HEXO Position: Q4 2022 in Review

Cambridge Investment Research Advisors sold out of HEXO Corp. Common Shares (HEXO) in Q4 2022, closing a stake of 988 shares — an estimated $2K sold.

Cambridge Investment Research Advisors first reported a position in HEXO in Q1 2019 and held it in 13 quarters. The position peaked at $120K in Q3 2019. 62 funds tracked by Wall St. Rank hold HEXO as of Q4 2022.

  • Cambridge Investment Research Advisors reported no remaining HEXO Corp. Common Shares position as of Q4 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 988 HEXO Corp. Common Shares shares in Q4 2022, an estimated $2K.
  • Cambridge Investment Research Advisors first reported a position in HEXO Corp. Common Shares in Q1 2019 and held it in 13 quarters.
  • Cambridge Investment Research Advisors's HEXO Corp. Common Shares position peaked at $120K in Q3 2019.
  • 62 funds tracked by Wall St. Rank held HEXO Corp. Common Shares as of Q4 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.